
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Revio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Peptris Technologies out-licenses AI-discovered drug candidate to Revio Therapeutics
Details : Under the licensing agreement, Revio will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS countries, which will be retained by Peptris.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 17, 2025
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Revio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
